EU/3/19/2190 : Orphan designation for the treatment of hepatitis D virus infection

Peginterferon lambda-1a


On 21 August 2019, orphan designation EU/3/19/2190 was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for peginterferon lambda-1a for the treatment of hepatitis D virus infection.

The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in October 2019.

Key facts

Active substance
Peginterferon lambda-1a
Intended use
Treatment of hepatitis D virus infection
Orphan designation status
EU designation number
Date of designation

Eigerbio Europe Limited
1 Castlewood Avenue
Dublin 6, D06 H685
Tel. +1 650 272 6138

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating